Fibronectin in HIV-infected patients: a prospective study

Area of Science:

• Infectious Diseases
• Immunology
• Clinical Biochemistry

Background:

• Fibronectin (FN) is a non-specific opsonin involved in microorganism clearance.
• Its role and diagnostic utility as a biomarker in human immunodeficiency virus (HIV) infection are not well-established.

Purpose of the Study:

• To prospectively evaluate plasma fibronectin levels in HIV-infected patients across different disease stages.
• To assess the diagnostic and prognostic value of plasma fibronectin in HIV infection.

Main Methods:

• Prospective study of 81 HIV-infected patients classified by CDC stages (Group II, III, AIDS, ARC).
• Plasma fibronectin levels measured using radial immunodiffusion assay.
• Comparison with 20 healthy controls and correlation with clinical/biological parameters (CD4+ cells, p24 antigen, beta-2-microglobulin, complement, immune complexes).

Main Results:

• No significant difference in mean plasma fibronectin levels between HIV patients (344 ± 128 mg/L) and controls (335 ± 45 mg/L).
• 79% of HIV patients had plasma fibronectin levels within the normal range, with no significant variation across CDC stages.
• No correlation observed between plasma fibronectin and CD4+ cell counts, p24 antigen, beta-2-microglobulin, complement levels, or circulating immune complexes.

Conclusions:

• Plasma fibronectin is not a useful biological marker for assessing infection or prognosis in HIV-infected patients.
• The study does not support the use of fibronectin as a diagnostic tool in the management of HIV.
• Further research may explore other potential biomarkers for HIV infection.